Financial Reports and Presentations

2026

2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2012
2011
2010
2009
2008
2006
2005
All years

Annual reports

Interim reports
Annual reports
Presentations
Other
All types

	Report
April 13, 2026Annual Report 2026 (in Swedish)

Investor contact

[email protected]

+46 18-50 54 40

Subscribe to our news

Investors

Now enrolling:

Paccal Vet hemangiosarcoma trial

A clinical study for dogs with splenic hemangiosarcoma

Learn more and take survey to see if you may qualify

Take me there

About Us
Projects and Technology
Corporate Governance
Investors
Media
Contact

Vivesto is a Swedish drug development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors. Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE).

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com